1. Home
  2. CAC vs PCRX Comparison

CAC vs PCRX Comparison

Compare CAC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAC
  • PCRX
  • Stock Information
  • Founded
  • CAC 1875
  • PCRX 2006
  • Country
  • CAC United States
  • PCRX United States
  • Employees
  • CAC N/A
  • PCRX N/A
  • Industry
  • CAC Major Banks
  • PCRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CAC Finance
  • PCRX Health Care
  • Exchange
  • CAC Nasdaq
  • PCRX Nasdaq
  • Market Cap
  • CAC N/A
  • PCRX 1.2B
  • IPO Year
  • CAC 1997
  • PCRX 2011
  • Fundamental
  • Price
  • CAC $45.61
  • PCRX $26.09
  • Analyst Decision
  • CAC Hold
  • PCRX Buy
  • Analyst Count
  • CAC 3
  • PCRX 10
  • Target Price
  • CAC $48.33
  • PCRX $29.30
  • AVG Volume (30 Days)
  • CAC 87.0K
  • PCRX 892.8K
  • Earning Date
  • CAC 01-28-2025
  • PCRX 02-27-2025
  • Dividend Yield
  • CAC 3.74%
  • PCRX N/A
  • EPS Growth
  • CAC 21.89
  • PCRX N/A
  • EPS
  • CAC 3.62
  • PCRX N/A
  • Revenue
  • CAC $177,396,000.00
  • PCRX $694,957,000.00
  • Revenue This Year
  • CAC N/A
  • PCRX $5.14
  • Revenue Next Year
  • CAC $10.12
  • PCRX $2.44
  • P/E Ratio
  • CAC $12.27
  • PCRX N/A
  • Revenue Growth
  • CAC 10.05
  • PCRX 4.40
  • 52 Week Low
  • CAC $28.62
  • PCRX $11.16
  • 52 Week High
  • CAC $50.07
  • PCRX $31.67
  • Technical
  • Relative Strength Index (RSI)
  • CAC 59.96
  • PCRX 77.75
  • Support Level
  • CAC $43.76
  • PCRX $25.06
  • Resistance Level
  • CAC $46.49
  • PCRX $27.10
  • Average True Range (ATR)
  • CAC 1.18
  • PCRX 1.45
  • MACD
  • CAC 0.24
  • PCRX 0.28
  • Stochastic Oscillator
  • CAC 81.18
  • PCRX 86.23

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Share on Social Networks: